Streetbeat News

Stock Prices

CCJ

Cameco's CEO highlighted the contrast between durable demand and fragile supply in the uranium market at the BMO Conference, reinforcing the company's decade-old message of strong long-term fundamentals due to increasing demand and tight supply.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 7:43 pm

CCJ

The CEO of Cameco, at the BMO Conference, stated that the tight market conditions on the supply side for their industry are expected to persist for a long time. This suggests a prolonged period of supply constraints.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 7:42 pm

COIN

GOOGL

IWM

MARA

RIOT

TLT

TSLA

Wall Street saw a subdued start to the week with major indices showing little change. The S&P 500 and Nasdaq 100 experienced minor adjustments, while the iShares Russell 2000 ETF (IWM) saw a slight increase. Treasury yields rose, impacting the iShares 20+ Year Treasury Bond ETF (TLT). In the stock market, Tesla (TSLA) and other EV stocks rallied, while Alphabet (GOOGL) fell due to concerns over its Gemini AI tool. Crypto-related stocks like Marathon Digital Holdings (MARA), Coinbase Global (COIN), and Riot Platforms (RIOT) surged alongside Bitcoin. Other notable movements included Palo Alto Networks (PANW) and R1 RCM (RCM) seeing significant gains.

Portfolio Pulse from Piero Cingari

February 26, 2024 | 7:35 pm

UPST

Financial analysts observed unusual options activity on Upstart Holdings (NASDAQ:UPST), with a bullish sentiment prevailing among traders. Analysis revealed 12 unusual trades, with 66% being bullish and 33% bearish. The trades included 5 puts valued at $292,336 and 7 calls valued at $290,372, targeting a price range of $16.0 to $50.0 for UPST. The largest trades included both bullish and bearish sentiments with varying strike prices and expiration dates. Upstart Holdings, a provider of AI-enabled lending platforms, has seen its stock price slightly decrease to $24.16. Analysts from JP Morgan and Piper Sandler have given UPST an average target price of $26.0, with ratings of Underweight and Neutral, respectively.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 7:30 pm

ON Semiconductor (NASDAQ:ON) has significantly outperformed the market with an average annual return of 23.18% over the past 10 years, turning a $100 investment into $825.56 today. The company's market capitalization stands at $32.89 billion.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 7:30 pm

GPN

Over the past 15 years, Global Payments (NYSE:GPN) has produced an average annual return of 15.72%, outperforming the market. A $100 investment in GPN 15 years ago would now be worth $922.38. The company currently has a market capitalization of $34.14 billion.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 7:30 pm

ACON

AGTI

AKLI

LUNR

PPC

TRNR

VERO

Pilgrim's Pride Corporation (NASDAQ:PPC) reported better-than-expected Q4 results with a 9.7% year-over-year sales growth to $4.528 billion and an adjusted EPS of 59 cents. Akili, Inc. (NASDAQ:AKLI) shares surged 116% after positive ADHD treatment trial results. Interactive Strength Inc. (NASDAQ:TRNR) rose 41% on a distribution deal with WOODWAY. Agiliti, Inc. (NYSE:AGTI) gained 29% after announcing a private acquisition by THL Partners. Aclarion, Inc. (NASDAQ:ACON), Intuitive Machines, Inc. (NASDAQ:LUNR), and Venus Concept Inc. (NASDAQ:VERO) saw significant share price drops due to various challenges.

Portfolio Pulse from Avi Kapoor

February 26, 2024 | 7:30 pm

CRM

Salesforce's stock price increased following Citigroup's decision to raise its price target for the company from $265 to $325.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 7:26 pm

ATUS

Altice USA shares have resumed trading, indicating a potential shift in market dynamics or response to a significant event.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 7:26 pm

SPRY

ARS Pharmaceuticals Inc (NASDAQ:SPRY) announced positive phase 2 results for its lead candidate, neffy, in treating chronic spontaneous urticaria, showing significant improvements in itch, hives, urticaria, and erythema scores. Neffy, an epinephrine nasal spray, was well-tolerated with mild to moderate adverse events. The company plans further studies towards FDA approval for allergic reactions, including anaphylaxis, with SPRY shares rising 5.15% to $8.78.

Portfolio Pulse from Vandana Singh

February 26, 2024 | 7:12 pm